Dr Keith E Halnan (Christie Hospital & Holt Radium Institute, Manchester) Radioiodine, X-ray Therapy, and Hormones, in Treatment of Thyroid Cancer The value of non-surgical treatment of thyroid cancer is sometimes doubted, partly because of its unpredictable and sometimes very slow progress. Two histories of patients seen in 1945 are relevant.
Case 1(45/3348) Woman aged 31 1945: She complained of a goitre growing rapidly for three months. A partial thyroidectomy for thyrotoxicosis had been done eight years before. On examination there was a large fungating tumour, coming from the lft lobe of the thyroid. Biopsy showed undifferentiated carcinoma. Radical X-ray treatment was then given over three weeks with a good immediate response. Further X-ray treatment was given two months later to recurrent tumour at the thoracic inlet. Since then she has remained well, having had a child in 1948. The patient was last seen in 1960, thus remaining well fifteen years after treatment of proved undifferentiated thyroid carcinoma.
Case 2 (45/3716) Woman aged 43 1945: Referred from Sir Geoffrey Jefferson with a cerebral tumour causing blurred vision, proptosis and a III nerve palsy. Biopsy had shown 'undifferentiated sarcoma'. X-ray treatment was given and there was no further progression of the eye symptoms. Pelvic bone metastases caused pain in 1946 and this, too, was relieved by X-ray therapy. The patient remained well for four years until the cerebral tumour caused symptoms again in 1950. A radioiodine test then showed uptake in both the skull and pelvis, as well as in neck and ribs. A partial thyroidectomy had been done in 1932 for thyrotoxicosis but nothing abnormal was palpable in the neck in 1945 or subsequently. A rib biopsy showed follicular adenocarcinoma. Radioiodine treatment was given with benefit until death occurred in 1952 from anemia with multiple bone metastases.
This shows the value of X-ray therapy in palliation, even when cure cannot be achieved, cerebral and bone metastases being kept under control for four years.
The histories have been reviewed of all patients with thyroid cancer seen at the Christie Hospital, Manchester from 1945 to 1955 inclusive. In these years there were only about 350 deaths per year in the whole of England and Wales, or just under 8 deaths per million population, certified as from thyroid cancer. The population of the Manchester Hospital Region has been about 4,000,000 to 4.500,000 so there should have been seen a maximum of 385 patients, or 35 per year; in fact there were 339, though from 1951 to 1955 the average was 36 per year. It seems likely, therefore, that this number will represent an almost complete group of cases. The only deficit may be a small number of patients with unsuspected differentiated carcinoma found to be malignant at operation or by the pathologist, and a few patients too ill for anything to be done.
During this period of eleven years the only change in the general policy for management of thyroid cancer was the introduction of radioactive iodine. Any patient with an operable thyroid cancer who was sufficiently fit underwent thyroidectomy. Almost all patients with inoperable cancer, whatever the histology, or with residual or recurrent tumours after surgery, were treated by X-ray therapy, radically if fit and almost always if the tumour was still confined to the neck. If there were known mediastinal direct extension or lymph-node metastases, the neck and appropriate part of the mediastinum were treated in one volume, including all known tumour. When there were distant metastases in, for instance, bone, lungs or brain, palliative treatment only was usually given.
Radioactive iodine came into use in 1948; most cases with metastases from differentiated cancer had tests and treatment if there was subgtantial uptake; several cases with undifferentiated tumours also had tests, but it soon came to be realized that treatment was rarely worth while. For almost all this period thyroid hormone treatment was only given for symptoms of hypothyroidism.
The cases have been classified into four stages. Stage 1 includes all cases where the tumour is still completely removable by radical surgery. It will include cases with and without early mobile lymphnode metastases, but the primary tumour will have remained within the thyroid gland. Stage 2 represents cases where the tumour is still confined to the neck, but is inoperable technically because of spread of either the primary tumour or lymphnode metastases to involve local structures, particularly the trachea, the cricoid and thyroid cartilages and the cesophagus; clinically the thyroid or lymph nodes or both are becoming fixed and immovable. Patients are classified as in Stage 3 when the tumour is known to have spread to the mediastinum either directly or by lymph-node metastases, and as in Stage 4 when there are distant metastases.
Histologically the tumours have been classified as differentiated, undifferentiated or mixed (Table  1) . Twenty-four untreated and 60 treated cases could not be satisfactorily classified, many of them having had no biopsy when seen in the earlier years reviewed. Thirty-nine patients were not treated because they were too ill or their disease too advanced (4 refusing treatment in addition). The mean survival was only 1-7 months; 18 were aged over 70 years, and 21 survived less than one month; only one lived as long as one year.
Eighteen patients were treated by surgery only. Ten of these were Stage 1. Two were not followed up, one was dead at one year, and 7 were alive at five years. One interesting Stage 3 patient with papillary cancer had a subtotal thyroidectomy and cervical block dissection, was seen to have mediastinal lymph-node metastases, not excised or treated in any way, but was alive eight years later. It is fair to point out that these good surgical results are not of great value in assessing the results of surgery since many patients who developed recurrence or metastases then had radiotherapy and are not included in this group.
The results as a whole, all cases whether treated or not, show that 26% survived five and 21 % seven years (Fig 1) . When comparing differentiated and undifferentiated cancer, the striking difference is not only the overall survival -52 % differentiated and 17% undifferentiated at five yearsbut also that the undifferentiated cases suffer considerable mortality in the first year or two, the differentiated in the third to seventh years.
The survival of all patients with undifferentiated cancer, treated by radiotherapy (some with previous surgery) is shown in Fig 2. There are only 7 operable cases (Stage 1) but of these 4 lived five years and 3 lived seven years; either surgery or X-ray therapy, or more likely both, must have a real value. Of Stage 2 cases, the tumour inoperable but apparently confined to the neck and capable of an attempt at cure by radiotherapy, about 20 % survive five years and 16 % seven years. Of Stages 3 and 4 (39 patients), it is surprising that any survive more than a year or two; in fact 3 lived four years and 2 seven years. It seems likely, but cannot be proved histologically, that these had lymphoreticular tumours, probably reticulum cell sarcoma, rather than anaplastic carcinoma. Of all the treatable differentiated cancers (Fig 3) only about half survive five years, ranging from 77 % of Stage 1 to 30 % of Stages 3 and 4. The fact that there are so many Stage 1 cases, 26 compared with only 7 undifferentiated, suggests the relatively slow rate of growth and metastasis. The difference between Stages 1 and 2 suggests the increased likelihood of cure after successful excision.
Hiirthle (or Askenazy) cellcarcinomas are generally accepted as a variant of differentiated adenocarcinoma, the cells, large acidophilic, finely granular, glandular epithelial, representing metaplastic thyroid epithelium. Of 9 patients with Hilrthle cell cancers in this series, 5 survived nine years. The behaviour of the tumours seems to fit in well with other differentiated thyroid adenocarcinoma. It-is sometimes thought that patients with the predominantly papillary adenocarcinoma have a better chance of survival than the follicular variety. The present series provides no evidence to support this, but confirms that the papillary cancer metastasizes to bone much less than the follicular variety and only rarely to the liver, although equally to lymph nodes and the lung.
Malignant thyroid lymphoma: The existence of this is still not fully accepted, but there is no doubt as to its clinical presence, there being a striking immediate sensitivity to X-ray treatment, comparable with that seen in Hodgkin's disease. Histological recognition and separation from diffuse small cell carcinoma is difficult. However, 11 cases were reported in this series, and though the number is small, the survival is twice as good as in the whole group of undifferentiated cancer.
The normal thyroid is not a radiosensitive tissue. Myxoedema is a very rare complication after the inclusion of the thyroid in the X-ray treatment of laryngeal and hypopharyngeal cancer. When deliberately attempting a medical total thyroidectomy or 'thyroid ablation' for cardiac disease or for thyroid cancer, a high radiation dose is necessary. Very few of the patients in this series who were treated by X-ray therapy only, without radioiodine or a total thyroidectomy, developed hypothyroidism. When carcinoma is treated, the radio-sensitivity very approximately varies in inverse ratio to the degree of differentiation. As always, there are exceptions, some undifferentiated cancers seeming completely resistant (perhaps they are really fibrosarcomas) and some differentiated tumours seeming sensitive.
X-ray therapy is always slow to take effect, with the usual initial latent period before any result is seen. One hopes for, but does not always see, a slow shrinking of the primary tumour, leaving an indurated tumour site. One side-effect of this is the return to normal of a previously compressed or deviated trachea. The great advantage of X-ray therapy compared with radioiodine is that the radiation is homogeneous and applied to the whole of the tumour, whereas radioiodine is concentrated patchily. The disadvantage of X-ray therapy is the necessity, even with carefully planned beamdirected treatment, of irradiating much normal tissue; it is particularly necessary not to treat the spinal cord to too high a dose. Radioiodine does, however, have great potential value in that widespread metastases throughout the body, known or unknown, can be successfully irradiated provided that they will concentrate iodine. Time is needed for this and a patient who is likely to die without treatment within three months will rarely derive benefit from radioiodine. X-ray therapy can act much more rapidly and can also be extremely useful in control of bone metastases causing severe pain, or in relief of a rapidly growing primary tumour causing dyspnea because of tracheal compression.
Radioactive iodine is of use almost solely in welldifferentiated thyroid cancer. During the period 1945-55 it has been used in Manchester only for patients in whom there is obvious inoperable cancer. It should be well accepted now that the first step in radioiodine treatment is thyroid ablation by surgery or radioiodine, to reduce competition for radioiodine from the normal thyroid, and to cause endogenous thyrotrophic hormone stimulation of the tumour by the patient's own pituitary gland as a result of hypothyroidism.
Thyroid ablation was done in 47 patients. Ten of those were Stage 1 cases; no uptake was seen subsequently, but it may have been that there was no tumour present in which to see uptake. Of the remaining 37 patients, uptake was seen and treatment given in 1 out of4 cases with undifferentiated cancer, in all 3 cases with mixed histology, and in 12 out of 30 cases with differentiated histology. Of the differentiated cases, uptake was observed in some patients from whom biopsies or thyroidectomy specimens had shown apparently pure papil-lary or Hurthle cell tumours as well as in the obviously follicular variety. Thus it seems likely that radioiodine treatment will be useful in something like 40% of suitable patients, i.e. of those who are well enough and who have inoperable or metastatic well-differentiated thyroid cancer.
In this group of patients, benefit from treatment can be clearly seen. In survival we have 4 patients out of 6 in Stages 1 and 2 alive at five years, and 6 out of 10 in Stages 3 and 4, compared with average survival in all treated patients with differentiated cancer of 55 % Stage 2 and 30 % Stages 3 and 4. Benefit is also seen earlier, in shrinkage of masses in the neck and elsewhere, radiological disappearance of lung metastases, and recalcification ofbone metastases. (Case histories were given showing these and other aspects.)
Hormone treatment has been used more widely during the last five years but it should be emphasized that long-term survival is quite possible without it. Most of the long-term survivors after X-ray therapy at Manchester have not, in the past, been given thyroid hormone.
Occasional cases, however, have clearly demonstrated the effect of thyroid hormone; the following history is one example: Case 3 (53/4478) Woman aged 62 Seen in 1953 with a past history of subtotal thyroidectomy five years before for a goitre that had then been present for fifteen years. A swelling had again appeared in the neck eight months before. A biopsy now showed differentiated follicular adenocarcinoma, and chest X-ray showed lung metastases. The patient was given X-ray treatment to the neck, and three successive treatment doses of radioiodine. The chest X-ray appearances did not change much, however, until suddenly, between January and April 1955, four and seven months after the last radioiodine, there was what the radiologist called 'a dramatic improvement'. Review of the history showed that this coincided with an increase in thyroid administration from gr A to gr 2 daily. The lungs remained clear for a year, when there was death from cardiac failure. Mr R S Murley (London) deplored the tendency of many authorities to advocate total thyroidectomy for all cases in which surgery was undertaken. He believed that there was littlejustification in so dogmatic an approach. In cases of welldifferentiated papillary carcinoma hemithyroidectomy with partial resection of the opposite lobe was often adequate, safer and more satisfactory. Whatever might be the views of a few highly experienced thyroid surgeons it was as well to remember that many of these cases would be handled by men of lesser experience. For this reason he suggested that it was more intelligent to avoid wholesale total thyroidectomy, and to encourage the surgeon to act according to his experience and judgment when the gland was fully exposed at operation. Mr Murley did not deny the occurrence of multicentric tumours, but he stated that such cases should not be allowed to colour the whole approach to thyroid carcinoma.
